COVID-19 Clinical Trials in Chicago, Illinois

7 studies are recruiting for covid-19 in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Dime La VerDAD: Verify, Debunk, and Disseminate

   Dime la Verdad (Tell me the truth) will evaluate the use of storytelling by community health workers as a communication strategy to disseminate reliable health information on social media and encourage informed decision-making in favor of recommended immunizations in communities with high morbidity…

   Stage

   Not phased

   Ages

   18 to 99

   Site

   University of Chicago, Chicago, Illinois

   Locations

   4 in total

   Run by

   University of Chicago

   See if you can join NCT06417762 on ClinicalTrials.gov

2. Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

   This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.

   Stage

   Phase 3

   Ages

   Any age

   Site

   Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

   Locations

   28 in total

   Run by

   Ansun Biopharma, Inc.

   See if you can join NCT03808922 on ClinicalTrials.gov

3. Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

   The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomar…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Illinois Research Network (ILLInet), University of Illinois Chicago, Chicago, Illinois

   Locations

   17 in total

   Run by

   Wes Ely

   See if you can join NCT06631287 on ClinicalTrials.gov

4. Dysbiosis & Long COVID

   The SARS-CoV-2 virus causes COVID-19, which ranges from mild initial symptoms to severe multi-organ dysfunction. While some patients recover to their baseline states, others develop a long COVID, or post-acute sequelae of SARS-CoV-2 (PASC) consisting of symptoms persisting >2-6 months post-infectio…

   Stage

   Not phased

   Ages

   18 to 80

   Site

   The University of Chicago, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT06825819 on ClinicalTrials.gov

5. A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection

   The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the University of Chicago.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT06008860 on ClinicalTrials.gov

6. EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

   The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/r…

   Stage

   Phase 3

   Ages

   0 to 17

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Locations

   73 in total

   Run by

   Pfizer

   See if you can join NCT05261139 on ClinicalTrials.gov

7. Convalescent Plasma as a Possible Treatment for COVID-19

   Patients who are ill with COVID-19 may benefit from receiving convalescent plasma infusions containing antibodies from donors who have recovered from the disease and are proven to no longer be infected. Given the current public health emergency due to COVID-19, the FDA has recently fast-tracked the…

   Stage

   Phase 2

   Ages

   40 and older

   Site

   University of Illinois at Chicago, Chicago, Illinois

   Run by

   University of Illinois at Chicago

   See if you can join NCT04442191 on ClinicalTrials.gov